International PCOS Network Renames Condition for 170 Million Women to PMOS

7 articles · Updated · BBC.com · May 31

Polyendocrine metabolic ovarian syndrome, or PMOS, is the new name adopted this month for PCOS, a shift advocates say better reflects the condition’s endocrine and metabolic effects beyond the ovaries.
Up to 1 in 10 women in the UK have the disorder, which is linked to irregular periods, excess hair growth, weight gain, fertility problems, high insulin levels and a higher later-life risk of type 2 diabetes.
Verity PCOS, which campaigned for the change for more than a decade, said the new name could help patients secure faster diagnosis and referrals to specialists such as endocrinologists.
Women living with the condition welcomed the move but said it must be matched by better support, after years of delayed diagnoses and being told to return only when trying to have children.

Will the PCOS name change to PMOS finally shift treatment from fertility to the entire metabolic and endocrine disorder?

It took 14 years to rename this condition. What does this reveal about the systemic challenges in women's healthcare?

Beyond a new name, can new diagnostic models truly end the years-long wait for a PMOS diagnosis for millions?